tag:blogger.com,1999:blog-781671514856579833.post7618759705511698948..comments2024-03-27T08:59:24.243-04:00Comments on Lympho Bob: Rituxan and BeyondLymphomaniachttp://www.blogger.com/profile/17519575154615844854noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-781671514856579833.post-52939368321727990742015-01-27T08:55:07.681-05:002015-01-27T08:55:07.681-05:00Thanks, Mel. We're doing OK so far -- not as m...Thanks, Mel. We're doing OK so far -- not as much wind and snow as they were predicting. Looks like things are a little rougher to our east.Lymphomaniachttps://www.blogger.com/profile/17519575154615844854noreply@blogger.comtag:blogger.com,1999:blog-781671514856579833.post-40188735239724532972015-01-26T20:12:53.776-05:002015-01-26T20:12:53.776-05:00Hi not related to FL but stay safe during the stor...Hi not related to FL but stay safe during the storm. My thoughts are with you <br />Mel from NZAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-781671514856579833.post-32023967159435824612015-01-25T18:03:47.873-05:002015-01-25T18:03:47.873-05:00Dear Karl Schwartz.
What a great new!!
Goodbye FLI...Dear Karl Schwartz.<br />What a great new!!<br />Goodbye FLIPI.<br />Rodrigo<br />Rodrigohttps://www.blogger.com/profile/03752723170397341265noreply@blogger.comtag:blogger.com,1999:blog-781671514856579833.post-4630410785516778262015-01-24T18:06:34.972-05:002015-01-24T18:06:34.972-05:00re Dr. Chen writes: "The introduction of ritu...re Dr. Chen writes: "The introduction of rituximab to the treatment of patients with non-Hodgkin lymphoma (NHL) in 1997 has doubled median survival to 10 years for individuals newly diagnosed with high-risk, low-grade follicular lymphoma."<br /><br />Hi Bob, Thanks as always for your thoughtful pieces. High risk FL is now thought to be associated strongly with treatment resistance (early relapse) ... based largely on the long or short duration of response to Rituxan-based treatment at 12 months. So for this reason I'm skeptical that the doubling of survival benefit for the addition of Rituxan is specific to high risk FL. More likely, it's the other way round.<br /><br />See ASH report 1664 Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era <br /><br />Karl<br />PAL www.lymphomation.orgKarl Schwartzhttp://www.lymphomation.orgnoreply@blogger.comtag:blogger.com,1999:blog-781671514856579833.post-71823412392390207682015-01-22T16:56:06.484-05:002015-01-22T16:56:06.484-05:00FLIPI is definitely NOT used to predict Overall Su...FLIPI is definitely NOT used to predict Overall Survival -- at least not directly. It's used in two ways, usually. The first is to group patients in clinical trials, so they are all at roughly the same place with their disease. (I think that's where the "high risk" categorization came from in this article.) The other way FLIP is used is by some doctors, who might base treatment decisions with FLIP as a guide. Low FLIP score = low risk = watch and wait. High FLIPI = high risk = CHOP. (That's just an example, of course. Individual doctors will make their own decisions.) <br />But it's not used to predict Overall Survival. Just too make factors that go into OS for ANY model to predict, especially since OS measures all survival, not just events related to cancer.Lymphomaniachttps://www.blogger.com/profile/17519575154615844854noreply@blogger.comtag:blogger.com,1999:blog-781671514856579833.post-4892218731040316622015-01-22T08:44:16.703-05:002015-01-22T08:44:16.703-05:00I didn't think the FLIPI Score was still used ...I didn't think the FLIPI Score was still used as a basis for predicting overall survival. Do you know if this is true or not? Thanks!Anonymousnoreply@blogger.com